# Saverio Minucci

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/324628/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 70<br>papers | 15,350<br>citations | 136740<br>32<br>h-index | 95083<br>68<br>g-index |
| 74<br>all docs | 74<br>docs citations | 74<br>times ranked | 28805<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer. Cell Death and Differentiation, 2022, 29, 614-626. | 5.0 | 20 |
| 2 | Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML. Oncogene, 2022, 41, 878-894. | 2.6 | 17 |
| 3 | SMARCA5 interacts with NUP98-NSD1 oncofusion protein and sustains hematopoietic cells transformation. Journal of Experimental and Clinical Cancer Research, 2022, 41, 34. | 3.5 | 14 |
| 4 | Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia. Bioorganic and Medicinal Chemistry, 2022, 56, 116596. | 1.4 | 8 |
| 5 | Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. European Journal of Medicinal Chemistry, 2022, 237, 114410. | 2.6 | 15 |
| 6 | Long nonâ€coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation. EMBO Reports, 2021, 22, e50852. | 2.0 | 21 |
| 7 | Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical Cancer Research, 2021, 27, 4311-4324. | 3.2 | 44 |
| 8 | Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. Cytokine and Growth Factor Reviews, 2021, 59, 1-8. | 3.2 | 4 |
| 9 | Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood, 2021, 137, 3093-3104. | 0.6 | 91 |
| 10 | Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis. Developmental Cell, 2021, 56, 2607-2622.e6. | 3.1 | 6 |
| 11 | Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer. Bioorganic Chemistry, 2021, 117, 105451. | 2.0 | 6 |
| 12 | LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response. Science Translational Medicine, 2021, 13, eabf7036. | 5.8 | 18 |
| 13 | MicroRNA-222 Regulates Melanoma Plasticity. Journal of Clinical Medicine, 2020, 9, 2573. | 1.0 | 10 |
| 14 | Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition. Haematologica, 2020, 105, 2105-2117. | 1.7 | 20 |
| 15 | Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acidâ€induced differentiation. Science Advances, 2020, 6, eaax2746. | 4.7 | 56 |
| 16 | Comparing apples with oranges: Studying LSD1 inhibitors in cellular assays. Pharmacological Research, 2019, 146, 104345. | 3.1 | 7 |
| 17 | Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. European Journal of Cancer, 2019, 122, 22-41. | 1.3 | 7 |
| 18 | Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3Î²-MCL-1 Axis. Cancer Cell, 2019, 35, 798-815.e5. | 7.7 | 212 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells. European Journal of Medicinal Chemistry, 2019, 165, 80-92. | 2.6 | 34 |
| 20 | Fumarate hydratase expression in localized, radically-resected clear cell renal cell carcinoma and its association with clinical outcomes.. Journal of Clinical Oncology, 2019, 37, 620-620. | 0.8 | 0 |
| 21 | Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. Nucleic Acids Research, 2018, 46, 3817-3832. | 6.5 | 31 |
| 22 | Epigenomic profiling of archived FFPE tissues by enhanced PAT-ChIP (EPAT-ChIP) technology. Clinical Epigenetics, 2018, 10, 143. | 1.8 | 16 |
| 23 | Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors. European Journal of Medicinal Chemistry, 2018, 155, 316-336. | 2.6 | 46 |
| 24 | Prognostic and predictive role of fumarate hydratase in metastatic clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 617-617. | 0.8 | 0 |
| 25 | c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. Clinical Cancer Research, 2017, 23, 2542-2555. | 3.2 | 105 |
| 26 | The Role of Chromatin-Associated Proteins in Cancer. Annual Review of Cancer Biology, 2017, 1, 355-377. | 2.3 | 10 |
| 27 | Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration. Journal of Medicinal Chemistry, 2017, 60, 1673-1692. | 2.9 | 59 |
| 28 | Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structureâ€“Activity Relationship. Journal of Medicinal Chemistry, 2017, 60, 1693-1715. | 2.9 | 60 |
| 29 | Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 575-581. | 1.5 | 17 |
| 30 | Synthetic Lethality Triggered by Combining Olaparib with BRCA2â€“Rad51 Disruptors. ACS Chemical Biology, 2017, 12, 2491-2497. | 1.6 | 28 |
| 31 | Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature Communications, 2017, 8, 593. | 5.8 | 175 |
| 32 | Entinostat for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2017, 26, 965-971. | 1.9 | 54 |
| 33 | Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model. Future Medicinal Chemistry, 2017, 9, 1161-1174. | 1.1 | 4 |
| 34 | A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. Epigenomics, 2017, 9, 1123-1142. | 1.0 | 125 |
| 35 | From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib. Frontiers in Pharmacology, 2017, 8, 718. | 1.6 | 23 |
| 36 | Mass-spectrometry analysis of histone post-translational modifications in pathology tissue using the PAT-H-MS approach. Data in Brief, 2016, 7, 188-194. | 0.5 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. Cancer Discovery, 2016, 6, 650-663. | 7.7 | 59 |
| 38 | Self-renewal of tumor cells: epigenetic determinants of the cancer stem cell phenotype. Current Opinion in Genetics and Development, 2016, 36, 92-99. | 1.5 | 18 |
| 39 | DNA binding modes of leukemia oncoproteins. Blood, 2016, 127, 177-178. | 0.6 | 2 |
| 40 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222. | 4.3 | 4,701 |
| 41 | Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. British Journal of Cancer, 2016, 114, 605-611. | 2.9 | 210 |
| 42 | Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. Journal of Medicinal Chemistry, 2016, 59, 1501-1517. | 2.9 | 70 |
| 43 | Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors. European Journal of Medicinal Chemistry, 2016, 108, 53-67. | 2.6 | 26 |
| 44 | Pathology Tissue-quantitative Mass Spectrometry Analysis to Profile Histone Post-translational Modification Patterns in Patient Samples. Molecular and Cellular Proteomics, 2016, 15, 866-877. | 2.5 | 41 |
| 45 | Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood, 2015, 126, 2392-2403. | 0.6 | 48 |
| 46 | Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. Antioxidants and Redox Signaling, 2015, 23, 15-29. | 2.5 | 13 |
| 47 | Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts. European Journal of Medicinal Chemistry, 2015, 94, 163-174. | 2.6 | 28 |
| 48 | Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews, 2015, 41, 754-760. | 3.4 | 19 |
| 49 | Tackling Oxidative Stress by a Direct Route: A New Job for HDAC Inhibitors?. Chemistry and Biology, 2015, 22, 431-432. | 6.2 | 2 |
| 50 | Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nature Communications, 2015, 6, 10044. | 5.8 | 108 |
| 51 | Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. ACS Medicinal Chemistry Letters, 2015, 6, 173-177. | 1.3 | 16 |
| 52 | Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A. European Journal of Medicinal Chemistry, 2014, 86, 352-363. | 2.6 | 50 |
| 53 | Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner. Nature Communications, 2014, 5, 5637. | 5.8 | 65 |
| 54 | Functional characterization of a novel FGFR1OPâ€RET rearrangement in hematopoietic malignancies. Molecular Oncology, 2014, 8, 221-231. | 2.1 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | PAT-ChIP coupled with laser microdissection allows the study of chromatin in selected cell populations from paraffin-embedded patient samples. Epigenetics and Chromatin, 2014, 7, 18. | 1.8 | 22 |
| 56 | Activation of a promyelocytic leukemiaâ€“tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nature Medicine, 2014, 20, 167-174. | 15.2 | 166 |
| 57 | Quantitative Chemical Proteomics Identifies Novel Targets of the Anti-cancer Multi-kinase Inhibitor E-3810. Molecular and Cellular Proteomics, 2014, 13, 1495-1509. | 2.5 | 14 |
| 58 | Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544. | 4.3 | 3,122 |
| 59 | HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature, 2011, 471, 74-79. | 13.7 | 368 |
| 60 | Fish the ChIPs: a pipeline for automated genomic annotation of ChIP-Seq data. Biology Direct, 2011, 6, 51. | 1.9 | 12 |
| 61 | Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2. Journal of the American Chemical Society, 2010, 132, 6827-6833. | 6.6 | 261 |
| 62 | Epigenetic therapies in haematological malignancies: Searching for true targets. European Journal of Cancer, 2009, 45, 1137-1145. | 1.3 | 45 |
| 63 | Determinants of Oncogenic Transformation in Acute Promyelocytic Leukemia: The Hetero-Union Makes the Force. Cancer Cell, 2007, 12, 1-3. | 7.7 | 11 |
| 64 | Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer, 2006, 6, 38-51. | 12.8 | 2,049 |
| 65 | PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood, 2002, 100, 2989-2995. | 0.6 | 103 |
| 66 | Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor. Science, 2002, 295, 1079-1082. | 6.0 | 754 |
| 67 | Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene, 2001, 20, 3110-3115. | 2.6 | 191 |
| 68 | Common themes in the pathogenesis of acute myeloid leukemia. Oncogene, 2001, 20, 5680-5694. | 2.6 | 72 |
| 69 | Oligomerization of RAR and AML1 Transcription Factors as a Novel Mechanism of Oncogenic Activation. Molecular Cell, 2000, 5, 811-820. | 4.5 | 273 |
| 70 | Fusion proteins of the retinoic acid receptor-Î± recruit histone deacetylase in promyelocytic leukaemia. Nature, 1998, 391, 815-818. | 13.7 | 1,015 |